Sayantan Ghosal, Adam Smith Chair in Political Economy, discusses an often-overlooked policy question: What is the relationship between aspiration failure and the continuation of poverty?
Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.
Here, Open Access Government maps out Switzerland’s research funding plans in 2020 onwards to maintain its position as a world leader in research, innovation, and education.
Open Access Government explores Thailand’s Department of Agriculture, and how it is a centre of excellence particularly regarding its research and development of rice cultivation.
Here, Open Access Government looks into European Commissioner Paolo Gentiloni’s priorities for strengthening the EU’s Economy while also putting citizens first, particularly in a time of crisis.
Dr Carlos Ziebert, Head of IAM-AWP’s Calorimeter Center, KIT, presents a holistic approach to how battery calorimeters can be applied all along the battery value chain.
Megan Warrender of Open Access Government explores Department for Business, Energy, and Industrial Strategy, led by Rt Hon Alok Sharma MP’s, priorities for energy policy in response to COVID-19.
Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
Manager EU Research at Centexbel, Guy Buyle introduces REMADYL, a H2020 project focused on the removal of legacy substances from PVC via a continuous and sustainable extrusion process.
The strides being made by the European Commission to achieve a digitalised society for all are explored by Assistant Editor of Open Access Government, Megan Warrender.
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
In this interview, David Engel from Full Moon Investments in the U.S., charts the firm’s successful targeted investment strategy – informed by industry-leading experience and expertise – including comments on the CBD hemp and medical cannabis space.